• Exclusive joint development agreement with Noramco, the world’s largest producer of chemically synthesized cannabinoids and pharmaceutical APIs, to commercialize biosynthesized CBD
• Willow is fully funded with $37 million and expects to have more than $15 million on the balance sheet once the biosynthesized CBD isolate is ready to sell as a product
• Experienced research team with historical expertise in developing a biosynthesized API derived from the opium poppy, from the bench level to commercial scale-up
• Established laboratories in Calgary and Vancouver, Canada, and in San Francisco, all undergoing expansion
• U.S. CBD market potential in excess of $66 billion by 2025 for cannabinoid-based APIs and CBD consumer retail goods

Willow Biosciences Inc. (CSE: WLLW) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://ibn.fm/G10ML) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

For more information, visit the company’s website at www.WillowBio.com

NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at http://ibn.fm/WLLW

• The cost of foodborne illnesses in the U.S. is estimated at more than $15.6 billion, with one in six Americans falling ill and roughly 3,000 dying from contaminated food and beverages annually
• High pressure processing plays an important role in food safety and is currently a $20 billion market; it is projected to reach $42 billion by 2026
• Independent research shows that PBIO’s Pressure Cycling Technology equipment can be used to dramatically reduce or eliminate common and well-known foodborne disease-causing bacteria
• The company’s new Ultra Shear Technology platform is being developed to make long-shelf-life milk and other dairy products
• Its Ultra Shear Technology has also been shown to make CBD oil “naturally” water soluble

Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of high pressure-based instruments, consumables and related services for the global life sciences and other industries worldwide, marked the first-ever World Food Safety Day by sharing several positive independent reports showing that its unique and patented pressure cycling technology (“PCT”) equipment is a formidable adversary when it comes to eliminating foodborne pathogens.

World Food Safety Day, an event adopted by the United Nations General Assembly and supported by international public health organizations including the U.S. Food and Drug Administration, took place on June 7, 2019 (http://ibn.fm/6hvQv). Several research presentations featuring PBIO’s HUB440 and HUB880 Explorer systems were delivered at the Institute of Food Technologists conference, an annual food science event held June 2-5, 2019, in New Orleans, Louisiana. Presentations centered on the use of PBIO’s unique, ultra-high pressure, PCT-based HUB equipment and the promising effect it has in high pressure processing food applications to inactivate foodborne pathogens.

Dr. Aliyar Fouladkhah, assistant professor and director of the Public Health Microbiology Laboratory at Tennessee State University, showed in a well-attended presentation that PBIO’s ultra-high pressure equipment can be used to dramatically reduce common and well-known foodborne disease-causing bacteria such as E.coli 0157 and Listeria monocytogenes, which are found in the presence of foods such as apple cider and chopped meat.

“Members of my public health microbiology research group and I were able to conduct and present results from our cutting-edge, innovative research projects to the most respected international food science conference thanks to the consistency, accuracy, and precision of PBIO’s HUB high pressure units and the collaborative endeavors with PBIO engineers and research scientists,” Fouladkhah stated in a news release (http://ibn.fm/PDu2F).

FDA Deputy Commissioner for Food Policy and Response Frank Yiannas said during his World Food Safety Day comments that, “Foodborne pathogens do not recognize boundaries or borders,” adding that approximately 125,000 children under the age of five die each year around the world because of foodborne illnesses (http://ibn.fm/V7Z6s). The U.S. Department of Agriculture estimates that the cost of foodborne illnesses in the U.S. is more than $15.6 billion annually (http://ibn.fm/P0RQE).

“The need for safer food is a worldwide concern,” Richard T. Schumacher, president and CEO of PBIO, stated. “We believe that presentations such as Dr. Fouladkhah’s at this year’s IFT Conference will help generate awareness of our new, powerful yet affordable bench-top HUB family of products in the food industry, government, military, and academic laboratory environment, and that this added exposure will result in an increased demand for our HUB equipment in this large and growing market.”

The company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT (pressure cycling technology) systems in over 200 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology.

In addition to the 17 or so patents that PBIO holds on its PCT platform, it also holds two patents in China for a second pressure-based technology – its novel Ultra Shear Technology (UST) platform. Patents have also been filed in the U.S. and many other countries worldwide. UST is a novel process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two or more insoluble liquids (like oil and water) soluble. UST is based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

Over the past few months, PBIO has released two short videos (http://ibn.fm/kVEML and http://ibn.fm/Mh3dc) showing how its patented UST platform was able to process CBD plant oil into a water-soluble nanoemulsion. When the UST-processed CBD oil was added to different liquids – such as a soft drink, a sports drink and a beer – the nanoemulsified CBD oil completely dissolved in each liquid.

UST holds great promise for many applications, such as making long-shelf-life stable milk and other dairy products, safer and better tasting beverages, and significantly more soluble and bioavailable CBD for use in foods, beverages, ointments and gels.

For more information, visit the company’s website at www.PressureBioSciences.com

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

• Wildflower Brands has signed an agreement with City Cannabis Corp. to acquire its issued and outstanding shares
• City Cannabis has been called the “fastest-growing multiple location cannabis retailer” in British Columbia
• Acquisition of shares is anticipated by leadership at both companies

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF), a Vancouver-based company developing and designing brands focusing on plant-based health and wellness products, has signed a share agreement with City Cannabis Corp. in order to acquire all of the issued and outstanding shares of City Cannabis (http://ibn.fm/4sHNR).

City Cannabis is continuing to grow, expanding its reach into the Vancouver cannabis market. The company is in the process of opening its fourth licensed dispensary in Vancouver, and its management team continues to examine other possible locations across the country. Currently, the company holds nine leases at varying stages of the regulatory licensing process.

Consideration for the acquisition consists of 60 million common shares of the company at a deemed price of $0.75 per common share. Wildflower’s acquisition of City Cannabis’ shares strengthens Wildflower’s status as an industry leader and brand-focused cannabis company.

“City Cannabis is no doubt the fastest-growing, multiple location cannabis retailer in British Columbia,” Wildflower CEO William MacLean stated in a news release. He referenced the acuity of the City Cannabis team in identifying key dispensary locations, as well as its industry knowledge and ability to work with all levels of regulators. “We look forward to completing the acquisition and bringing together two phenomenal companies,” he added.

“This is an exciting moment for everyone, and we are thrilled to be joining the Wildflower team,” said City Cannabis CEO Krystian Wetulani. “We believe Wildflower’s branding and marketing expertise will drive growth once City Cannabis is integrated, resulting in significant long-term value to Wildflower shareholders.”

Wildflower Brands utilizes a comprehensive business model that encompasses research and development, manufacturing, distribution, marketing and retail. The company’s holdings include Wildflower Wellness, which offers a complete line of full-spectrum, CBD extract-infused products; King Extracts, a California-based company focused on cannabis technology and delivery systems; and licenses in Los Angeles and California to operate cultivation, manufacturing, distribution, retail and delivery.

City Cannabis is a cannabis retailer holding two of the six City of Vancouver licenses in the province of British Columbia. The company has been turning a profit in dispensary operation since Vancouver started licensing cannabis retailers. Upon closing of the share acquisition, Wildflower intends to appoint Wetulani as a director and chief development officer.

For more information, visit the company’s website at www.WildflowerBrands.co

NOTE TO INVESTORS: The latest news and updates relating to WLDFF are available in the company’s newsroom at http://ibn.fm/WLDFF

• A partnership with PAX will allow Organigram to manufacture and fill pods for the premium, technology-based PAX Era vaporizer
• The PAX partnership is expected to enable the two entities to seize new opportunities on the market and work together to develop premium products featuring disruptive, industry-leading technology that is set to redefine the experience of vaping
• An agreement signed with Feather Company Ltd. makes Organigram the exclusive Canadian supplier of unique and proprietary vaporizer pen technology
• Organigram is selling to all 10 Canadian provinces
• The company is on track to increase production capacity and is well positioned for Canada’s new edibles and derivative legislation, slated for October 2019

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI), a leading Canadian licensed producer (LP) of high-quality cannabis and extract-based products, continues to develop exclusive partnerships and introduce innovative products that enhance the cannabis lifestyle for its customers. An exclusive agreement signed with Feather Company Ltd. illustrates this laser focus on customer experience as Organigram looks forward to Canada’s legalization of new cannabis product categories, as the company stated in a news release (http://ibn.fm/T4kfV).

“A successful recreational cannabis market requires that licensed producers and their partners continually reimagine the cannabis experience,” Ray Gracewood, senior vice president, marketing and communications for Organigram, stated in the release. “It is critical for Organigram to find unique ways to offer customers the kind of value that will help differentiate our brands. The future is in providing unique opportunities for customers to explore the product.”

The exclusive agreement between Organigram and Feather, a cannabis innovator and lifestyle brand committed to the production of premium-quality products, creates a mutually beneficial relationship for the two companies. Organigram, through its Edison Cannabis Co. brand, will hold an exclusive license to Feather’s proprietary vaporizer pen technology and form factor. Organigram will also represent Feather across Canada from a commercial perspective and plans to approach all 10 provinces with Feather’s disposable and cartridge-based units.

“We are thrilled to be working with Organigram,” Feather CEO Patrick Lehoux stated in the release. “As patients, enthusiasts and advocates for the cannabis community, we are committed to applying our diverse skills to produce the best experience for consumers. Our partnership with Organigram opens new and exciting opportunities for us to do just that. We believe in the Edison brand and Organigram’s best-in-class facility ensures that we are partnered with a team committed to producing a consistent, premium product.”

The disposable vaporizer pen and 5/10 thread cartridges for targeted adult-use customer segments are expected to be available as this product category becomes legal in Canada by mid-October 2019. Feather’s technology and hardware offers Organigram’s Edison brand a unique, proprietary delivery mechanism for discerning and sophisticated consumers and will complement the company’s partnership with PAX, a leader in closed-loop vaporizable technology offered through the PAX Era product line  (http://ibn.fm/lXIpJ).

Organigram is planning on working with and offering the Edison Cannabis Co.-branded PAX Era pods to all 10 of its provincial partners to achieve coast-to-coast distribution. The pods will be filled onsite at Organigram’s Moncton facility at the company’s phase 5 refurbishment.

As concentrates are anticipated to become legal in Canada later in 2019, giving birth to a wide range of new market development opportunities, strategic partnerships like the one between Organigram and PAX Labs are expected to allow the immediate launch of premium products featuring a disruptive, industry-leading technology that is set to redefine the experience of vaping.

“Cannabis 2.0 – the next generation of legal, adult use cannabis products – represents a world of opportunity,” Organigram CEO Greg Engel added. “Innovative partnerships with exceptional companies like PAX mean our own product offering grows and our customers have access to cutting-edge technology and cannabis experiences.”

The agreement with PAX reflects Organigram’s strategic commitment to growth and leadership through technology-driven innovation. Additionally, the company has been building up significant levels of concentrate in anticipation of the Canadian legislative change and the launch of Cannabis 2.0 vape pens and edibles later in 2019. According to Engel, this is just the beginning for his company, whose team is strongly committed to developing exceptional and imaginative products that support both the organization’s business objectives and its customers’ needs.

Further cementing its position, Organigram earlier in 2019 secured distribution agreements in all 10 Canadian provinces, becoming one of just three licensed producers in Canada to do so (http://ibn.fm/NCowK). The company boasts the lowest cost of cultivation among Canadian licensed producers, driven by industry-leading yields.

For more information, visit the company’s website at www.Organigram.ca

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://ibn.fm/OGRMF

• CIIX is the first CBD company to focus on Chinese-speaking North Americans
• The company is targeting a huge market opportunity in China and throughout Asia
• CIIX sales are projected to double over the next 12 months

ChineseInvestors.com Inc. (OTCQB: CIIX) provides Chinese-speaking investors in the U.S., Canada and Asia with real-time market commentary, analysis and education-related services in the Chinese language. The company has a highly diversified revenue stream and is seeing a huge market opportunity for its cannabinoid products, as well as expanding into cryptocurrency and blockchain educational services.

In 2019, CIIX experienced an 81 percent revenue increase, which CEO Warren Wang attributed mainly to the company’s hemp CBD sales. The company is standing at the forefront of this market as the first CBD company to focus on the more than four million Chinese-speaking Americans and Canadians.

On May 1, 2019, under wholly owned subsidiary ChineseHempOil.com, which has been doing business in the United States since 2017 as Chinese Wellness Center (CWC), the company opened its first mall pop-up kiosk. The kiosk offers customers CWC’s OptHemp product line and additional CBD products including NuLeaf Naturals, Joy Organics, Medterra, Hemp Meds and Medix.

Right now, a huge market opportunity exists in China and throughout Asia. The Chinese consumer has high spending power, and regulations are in favor of CBD products in China. CIIX reports additional mergers and acquisitions in the planning stages in Asia.

By focusing on the American market and opportunities in China and Asia, the company’s sales are projected to double over the next 12 months, Wang noted in a news release (http://ibn.fm/2UeEH). U.S. consumer sales of CBD are anticipated to reach $1.8 billion by 2022, increasing drastically from the $500 million seen in 2018 (http://ibn.fm/q72dL). The industry is rapidly growing, and CIIX has positioned itself strategically as the first publicly traded Chinese company to offer CBD to an American market.

CIIX’s main focus is on providing financial information and services to the global Chinese community. The company continues to develop and market web-based tools to educate and inform while providing added value to an everchanging market. The following educational tools are provided in the Chinese language character set:

• Da Ma Dian Ping is a cannabis-focused mobile app that’s currently in the developmental stage. This app will aim to provide Chinese speakers worldwide with the ability to review and discuss cannabis products.
• www.NewCoins168.com is a free portal that offers news and investment education covering cryptocurrency and blockchain.
• www.ChineseInvestors.com is the company’s primary site, offering real-time market information and educational services.
• www.ChineseFN.com offers daily financial investment news and has 5,000 subscribers and more than 100,000 registered users.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

• PLUS has the right (but no obligation) to buy Emerald Bay Wellness and Emerald Bay Extracts’ business assets
• Emerald Bay Extracts has been one of Plus Products’ largest suppliers for the past year
• If the option is exercised, PLUS will reap the benefits of vertical integration and directly interact with the cannabis plant

Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF), manufacturer and marketer of cannabis food products, has purchased an option to buy California-based cannabis oil manufacturer Emerald Bay Wellness LLC and the business assets of Emerald Bay Extracts. The option specifies cash and stock consideration to acquire one of PLUS’ largest cannabis oil suppliers and a supply partner of more than one year (http://ibn.fm/IH7B3).

In consideration for the option, PLUS will deliver a $400,000 secured loan to Emerald Bay Extracts. If the option is exercised, terms call for the issuance of approximately 1.2 million subordinate voting shares of PLUS and $250,000 in cash; in addition, Emerald Bay would not be required to repay the loan. Some 70 percent of the deal’s consideration would be subject to performance targets including revenue, which totals almost $28 million over a two-year earn-out period.

“We targeted this acquisition because it allows us to reap the benefits of vertical integration while maintaining a focus on product manufacturing,” PLUS CEO Jake Heimark stated in a news release. “Ultimately, this is a rare opportunity to improve quality control, cut costs and grow revenues all at the same time.” Acquiring Emerald Bay would give PLUS the opportunity to “directly interact with the cannabis plant,” Heimark added.

PLUS said that, if the option is exercised, it would give the company in-house cannabis extraction capabilities that would improve quality control and raise gross margins on its core edibles business. Exercising the option could also create a new revenue stream and expanded new-product development capabilities.

San Mateo, California-based PLUS is a cannabis-infused, branded products manufacturer selling to regulated medicinal and adult-use recreational markets in California and Nevada. PLUS is focused on building the largest cannabis brand by growing organically and through acquisitions.

For more information, visit the company’s website at www.PlusProducts.com

NOTE TO INVESTORS: The latest news and updates relating to PLPRF are available in the company’s newsroom at http://ibn.fm/PLPRF

• The presentations were held during the annual American Society of Mass Spectrometry conference – an event attended by more than 10,000 scientists
• Research focused on a wide range of applications ranging from cancer research to biomarker discovery
• The number of PCT-related presentations during the 2019 conference exceeded prior Pressure BioSciences records for a scientific meeting, demonstrating the platform’s broad applicability potential

Pressure BioSciences Inc.’s (OTCQB: PBIO) patented pressure cycling technology (PCT) platform was featured prominently in 15 independent scientific presentations delivered during the annual conference of the American Society of Mass Spectrometry (ASMS) that took place June 1-6, 2019 in Atlanta, Georgia, as the company announced in a recent press release (http://ibn.fm/vLiCW).

The ASMS annual meeting is a highly reputable conference attended by more than 10,000 scientists from around the world. It is a showcase event for new research and scientific findings that has been held every year since 1953.

This year’s PCT-involving presentations spanned a range of applications – from cancer research to molecular biology and biomarker discovery. Of the 15 presentations, nine focused on the importance of PBIO’s PCT platform in cancer research. Three of these presentations put emphasis on the use of streamlined sample preparation protocols and systems featuring Pressure BioSciences’ Barocycler 2320EXT instrument and its associated and proprietary MicroTubes.

Data suggest that the use of the PCT platform accelerates and strengthens protein analysis, improving cancer characterization and providing clinically relevant information at the end of the trial.

Researchers from both Australia and China reported advances in their cancer diagnostic programs. These programs are reliant on the PBIO PCT platform for the rapid extraction of proteins from tumor tissues for the purpose of analysis and treatment guidance.

Pressure BioSciences PCT platform was also used in studies aiming to provide more clarity on the racial disparities in cancer. Through such studies, medical professionals could eventually start offering better early screening and detection opportunities among minority groups.

A few other presentations focused on cancer biomarker discovery and protein/molecular biology research.

“The number of PCT-related presentations at the 2019 ASMS conference significantly exceeded prior PBI records for a scientific meeting. We are gratified that the use of our PCT platform continues to expand to new investigators and laboratories worldwide, and that its use has shown great promise in critical areas of human health, such as cancer,” Pressure BioSciences Global Director of Sales and Marketing Roxanna McCloskey said in a news release.

Being featured during presentations at such a prestigious scientific event shows the increasing potential of the PCT technology in diagnostics and discovery, according to McCloskey. The Pressure BioSciences team believes that such platforms could eventually be utilized routinely in precision medicine, a field that’s expanding rapidly and is anticipated to reach a volume of $216.75 billion by 2028, according to BIS Research (http://ibn.fm/FbaSz).

Pressure BioSciences is a leader in the development of innovative pressure-based solutions for the global life sciences industry. The company’s products are based on the properties of static and alternating hydrostatic pressure. PCT is a patented technology platform that uses alternating cycles of hydrostatic pressure to control bio-molecular interactions. Pressure BioSciences’ primary goal for the platform is the development of PCT-based products for biomarker discovery, drug development, biotherapeutics, forensics and soil and plant biology, to name but a few areas of focus and interest.

For more information, visit the company’s website at www.PressureBioSciences.com

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

• In line with Health Canada’s amended cannabis regulations, Supreme Cannabis has reaffirmed its expanded product strategy
• Supreme Cannabis plans to debut a range of cannabis extract offerings, including vaping liquids, concentrates, oils and tinctures
• Health Canada’s amended regulations permit the legal production and sale of three additional types of cannabis products, including cannabis edibles, extracts and topicals

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) is prepared to meet Health Canada’s amended cannabis regulations, which include three additional types of cannabis products: cannabis edibles, extracts and topicals (http://ibn.fm/oOVOm).

The company’s strategy is to target premium brands, leverage its coast-to-coast distribution in Canada and expand into the international cannabis market. Supreme Cannabis’ expanded product strategy includes adding high-quality cannabis extracts, including vaping liquids, concentrates, oils and tinctures, to its brand portfolio.

Supreme Cannabis also plans to enter the extracts category through its agreement with vaporizer firm Pax Labs Inc. Terms of the agreement call for Supreme Cannabis subsidiary 7ACRES to become one of only four licensed producers to supply cannabis pods for the PAX Era vaporizer in Canada.

Supreme Cannabis also intends to commercialize and develop a product lineup that includes extracts and oils through its partnership with Khalifa Kush Enterprises of Canada ULC. Its proposed acquisition of Blissco Cannabis Corp. will also provide for new product development – under the Blissco brand – of oils and topicals for the wellness consumer.

Regarding the cannabis extracts market, Supreme Cannabis CEO Navdeep Dhaliwal said in a news release, “Supreme Cannabis has positioned brands, secured partnerships and developed inputs to address this meaningful segment of the market and introduce high-quality cannabis products as early as possible.” Dhaliwal added that the cannabis-extracts market represents some 35 percent of industry sales in some legal U.S. states.

New Health Canada regulations are expected to come into effect October 17, 2019. On July 15, license holders can start to submit requests for license amendments. On October 17, license holders can begin to submit new product notifications. Mid-December 2019 is the earliest anticipated date when new products can be sold, per a Health Canada release (http://ibn.fm/omcB6).

Supreme Cannabis is a Toronto-based company that is focusing on pursuing opportunities and generating sustainable growth in what it sees as an emerging global market.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

• The Federal Aviation Administration has granted Uber and San Diego, California, permission to test food delivery via drone services
• Uber partnered with McDonald’s and completed the first phase of testing at San Diego State University
• Uber made this announcement after Amazon announced similar plans to commence drone delivery services

Uber Technologies Inc. (NYSE: UBER) has completed its initial phase testing for food delivery via drones for Uber Eats (http://ibn.fm/cx2J3), at San Diego State University. This testing was done in collaboration with McDonald’s, after the Federal Aviation Administration granted Uber the drone testing rights. Uber plans to include other Uber Eats food and delivery partners in the future while leveraging the expertise and technology of Uber Elevate.

Uber Eats will use drone services for only a part of the delivery journey. Once the food is prepared as per the order placed by the customer, it will be loaded in the drone. The drone will then carry the food to a predetermined central location, from where manual deliveries will be done. Meanwhile, Uber’s Elevate Cloud Systems will monitor and guide the drones, as well as informing Uber Eats delivery drivers of the delivery points and times of food deliveries. This point of landing is likely to be the rooftop of an Uber vehicle. The delivery person will then collect and hand-deliver the food at the notified address.

In a statement released by Uber, Luke Ficher, Uber Elevate’s head of flight operations, said that the company was complying with the strict regulations and safety measures detailed by the FAA. He further stated that Uber envisions providing Uber Eats services to a greater number of people in a safe and convenient manner.

Using drone services for food delivery indicates that Uber intends to implement mammoth expansion plans. Eats is one of the most profitable ventures of Uber, recording gross booking growth of 108 percent to $3.07 billion in Q1 2019 (http://ibn.fm/lNXfL). Uber envisages extending Uber Eats services in densely populated urban areas where doorstep delivery is not feasible. With the huge network of Uber Eats delivery and restaurant partners and Uber Elevate technology, Uber is uniquely positioned to take on this challenging role.

For more information, visit the company’s website at www.Uber.com

• Sharing Services Global is building a social connectivity model through its growing direct sales portfolio, encouraging home-based entrepreneurship and widespread consumer activity
• Sharing Services’ Elevacity brand is part of a $12 billion trend in wellness consumerism that provides healthy products and services
• The direct sales industry generated $35.4 billion in retail revenues during 2018, up 1.3 percent over the prior year, and Sharing Services’ revenues have been marking record month-over-month increases

The technological revolution of the past two decades has reimagined the landscape of social experiences. People have focused a growing measure of time and work on documenting the details of their lives, whether marvelous or mundane, so they can share photos and stories with an expansive network of acquaintances via electronic media platforms. An irony of the reimagined social network is that people may be strongly connected to each other across thousands of miles while virtually unaware of other persons within close physical proximity to them at the same time.

Within the social circle revolution, direct sales’ emphasis on personalized shopping experiences has taken on a new degree of importance, as evidenced by the financial strength of direct sales innovator Sharing Services Global Corporation (OTCQB: SHRG) and its homespun Elepreneur network of independent sales associates.

Sharing Services is a multi-million-dollar operation that owns or controls an interest in companies that sell a wide array of products and services directly to the consumer, including health and wellness offerings.

The Elepreneurs elevate the company’s home-based business entrepreneurship model, furthering a model through which diverse market components work together synergistically in a common market universe.

The result of Sharing Services’ friendly, enthusiastic sales approach has been a string of monthly revenues records for the company, mirroring larger success trends for direct sellers in general.

The Direct Selling Association, a national trade association for companies that offer entrepreneurial opportunities to independent sellers, recently reported that retail sales and the number of people selling and purchasing products and services through the direct sales channel are all experiencing solid growth.

The report states that direct sales generated $35.4 billion in retail revenues during 2018, up 1.3 percent from 2017. It likewise notes that the number of direct sellers grew by 1.6 percent to more than six million people in the United States, and that there were more than 36.6 million people actively buying through direct sales channels during the year (http://ibn.fm/2mg7i).

“Retail sales were strong, thanks largely to the U.S. direct sales force and their ability to attract millions and millions of customers,” Direct Selling Association President and CEO Joseph N. Mariano stated in a release. “As we look forward and evaluate industry data, as well as national economic and retail projections, we believe the industry will continue to see modest growth during the next three years.”

The organization noted that the number of people involved in direct selling in the United States grew by 31.4 percent from 2011 to 2016, outpacing U.S. retail sales growth, and that people involved in direct selling have a higher than average percentage of annual incomes over $50,000, at 58 percent, according to Sharing Services (http://ibn.fm/c5EZl).

Wellness products and value-added services make up the most lucrative sectors of the direct selling industry. Sharing Services’ Elevacity brand, promoting such wellness products, is part of a market that commanded $12 billion in total sales during 2016.

To build on the company’s successes, Sharing Services has filed an application to uplist its stock to the Nasdaq Capital Market (http://ibn.fm/16rGf).

“We have made significant progress in strengthening our financial performance, governance and liquidity in the last 18 months since rebranding and launching our first two companies to position us for continued growth and profitability… A listing on the Nasdaq Capital Market is a natural progression for the company and our shareholders,” CEO John “JT” Thatch stated in a news release (http://ibn.fm/lVozo).

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG